Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CODOX-M/R-IVAC versus DA-EPOCH-R for newly diagnosed high-risk Burkitt lymphoma
NL-OMON28081Phase 3Recruiting
- Sponsor
- HOVON
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, vincristine, doxorubicin, methotrexate and 4 more in Burkitt lymphoma (BL) (2 arms), sponsored by HOVON. Primary endpoint: Progression-free survival at 2 years. Started Jun 2014; status: recruiting.
02
Drugs
rituximabcyclophosphamidevincristinedoxorubicinmethotrexate
03
Conditions
Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NL-OMON28081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28081.